Skip to main content
. 2020 Apr 19;21(8):2856. doi: 10.3390/ijms21082856

Figure 1.

Figure 1

Immune-checkpoint inhibitor approval status by the Food and Drug Administration (access date: 03/13/2020). A: accelerated, AB: antibody, CTx: chemotherapy, dMMR: mismatch repair deficiency, HCC: hepatocellular carcinoma, HL: Hodgkin’s lymphoma, HNSCC: head and neck squamous cell carcinoma, MSI-H: microsatellite instability, NSCLC: non-small cell lung cancer, PMBCL: primary mediastinal B cell lymphoma, R: regular, RCC: renal cell carcinoma, TKI: tyrosine kinase inhibitor.